- I2PURE Chemistry
- The Science
- Product Pipeline
- Documentation -
- BioTech vs Microbes
- The Power of Science
- Completed Science
- Dr. Kessler Published Manuscripts -
- 02/03/22 - Journal of Hospital Infection
- J. Pharm. Pharmacol
- Journal of Hospital Infection
- The Breast Journal
- Thyroid
- Thyroid
- International Journal of Pharmaceutics
- The Journal of Biological Chemistry
- 3rd Party Test Results -
- Request the Cytotoxicity Study
- Request the ASTM E2315 Bacteria Panel Report
- Request the ASTM E2755 Persistence Report
- Request the SARS CoV-2 Report
- Blog
- News
- Company Info
I2PURE News
Our newest manuscript published in the Journal of Hospital Infection
Molecular iodine is not responsible for cytotoxicity in iodophors
Journal of Hospital Infection - February 4, 2022
For the last 67 years, there has been a lack of accurate information presented to global healthcare providers regarding molecular iodine. This foundational manuscript in The Journal of Hospital Infections will begin to contextualize molecular iodine for the first time.
The conclusion of the manuscript: "The maximum concentration of I2 found in diluted PVP, about 25 ppm, is not cytotoxic or irritating. The potential clinical utility of I2 has been limited by incorporating this broad-spectrum biocide in acidic aqueous formulations that contain numerous chemical species that contribute toxicity but not biocidal activity. I2 can be delivered topically into hypodermis tissue without irritation."
Read the manuscript
For those researching PVP-I
In consideration of your research using PVP-I, we would like to introduce you to an iodine formulation that has stabilized molecular iodine (I2) without the presence of complexing agents or other iodine species.
I2PURE is a biotechnology company on a mission to provide a means of combating effects of pathogens on global societies.
The I2PURE platform is being developed for OTC, therapeutic, medical device and agricultural usage.
I2PURE’s molecular iodine chemistry creates a non-staining, non-irritating, efficacious ingredient with 1,500 ppm of active I2. It is third party certified nontoxic in a 24-hour in vitro cytotoxicity study.
- ASTM E2315 Biocide against bacteria 99.999%
- EN 14476 Virucide against SARS-CoV-2 99.999%
- ISO 10993-5-2009 non-toxic
- ASTM 3058 sampling Persistent past 6 hours / At 6 hours killed 90.3% of the Staphylococcus aureus applied to hands in 1 minute
If you are researching PVP-I, our material may hold some interest to you as it delivers the active without any of the toxic components. We would welcome the opportunity to talk with you and/or send you a sample of our formulation for your review.
I2PURE recognized as the Runner Up winner in the Tech Venture category.
Loudoun Economic Development - July 28, 2021
We are a winner in the second annual Loudoun Innovation Challenge and have taken the Tech Venture category top spot. This year had an enormous amount of competition with a total of 156 applicants. We are thrilled to have stood out among so many inventive and forward-thinking businesses.
This competition is designed to recognize Loudoun County Virginia local companies that are rethinking the status quo in their industries.
“This is a tremendous honor for I2PURE, and the recognition of I2PURE’s innovation, mission and work during the startup phase is gratifying,” CEO Douglas Spitz said. “From its inception, I2PURE has been privileged to call Loudoun County home. We have been welcomed here since day one and cannot imagine growing our global biotechnology company anywhere else”.
Thank you so much Loudoun County Economic Development Authority, in partnership with Loudoun Economic Development. We are honored!
